The power of CRISPR became definitively clear when the first CRISPR-based gene therapy, Casgevy (exa-cel), won regulatory approvals for the treatment of sickle cell disease. But CRISPR’s applications ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

Two recent studies identified gene knockouts that may make CAR T-cell therapy more effective, but the next step is applying the hypotheses in humans.

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic ...

Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile--The AATD ...

CRISPR Therapeutics has developed SyNTase editing ... off-target effects. In a humanized mouse model, SyNTase editing components encapsulated in a lipid nanoparticle (LNP) enabled highly efficient, ...

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic ...

CRISPR Therapeutics (CRSP) announced the acceptance of an abstract for oral presentation at the European Society of Gene and Cell Therapy, ESGCT, ...